Treating Patients with Venous Thromboembolism: Initial Strategies and Long-Term Secondary Prevention

ABSTRACT

Therapy for venous thromboembolism (VTE) currently involves a minimum of 3 months of anticoagulation. After cessation of therapy, however, recurrent venous thrombosis occurs at rates of 6 to 9% per year. Clinical trials have demonstrated the benefits of extending anticoagulation beyond 3 months for the prevention of recurrent VTE events. Despite this, many eligible patients do not receive the required thromboprophylaxis and the incidence of recurrent VTE remains too high for a preventable condition. A reason for failure to use prophylaxis is the fear of bleeding complications with current oral anticoagulants such as warfarin. Warfarin has an unpredictable pharmacokinetic profile and a variable dose-response relationship that requires frequent coagulation monitoring and dose adjustments to maintain a target intensity that is both safe and effective. Alternative strategies for long-term prophylaxis, which may potentially provide more consistent anticoagulant responses and reduce coagulation monitoring requirements, include the use of low-molecular-weight heparin (LMWH), treatment with warfarin at a lower intensity, and the introduction of novel anticoagulants. The long-term use of LMWH has been found to be a particularly favorable treatment option for cancer patients in whom it is difficult to control the intensity of anticoagulation. In clinical trials, LMWH significantly reduced the risk of recurrent VTE without increasing bleeding risk. The parenteral administration of the LMWHs, however, is a drawback for long-term use in the outpatient setting. A clinical trial assessing the efficacy and safety of long-term low-intensity warfarin treatment found this therapy to be better than placebo, but another study showed that conventional intensity warfarin was significantly more efficacious than low-intensity warfarin. New therapies in development that may offer improved safety-efficacy profiles are the synthetic pentasaccharides fondaparinux and idraparinux and the oral direct thrombin inhibitor ximelagatran. Parenterally administered fondaparinux has been shown to be as effective as LMWH for the acute treatment (5 to 7 days) of symptomatic deep vein thrombosis. Idraparinux, with once-weekly parenteral dosing, is currently being assessed in phase III clinical trials for the long-term secondary prevention of VTE. Ximelagatran is the first oral agent in the new class direct thrombin inhibitors. With a fast onset of action and oral administration, ximelagatran is a candidate for both acute and chronic therapy. The Thrombin Inhibitor in Venous Thromboembolism (THRIVE) clinical trial program has demonstrated that this agent has a favorable benefit-risk profile compared with standard therapy for the initial treatment (6 months) and secondary prevention (up to 18 months) of VTE. However, in a substantial proportion (6 to 13%) of patients given extended ximelagatran therapy, elevated serum transaminase enzymes developed, typically in the first 2 to 4 months of treatment. Even though these elevations usually abated without clinical sequelae whether or not treatment was continued, their clinical relevance remains unclear. In addition, locally reported coronary events occurred more frequently in ximelagatran-treated patients during the initial 6 months of treatment, the reason for which is yet unclear. The consistent anticoagulant response and fixed oral dosing without coagulation monitoring allows ximelagatran to overcome many of the limitations inherent to current treatment options for VTE treatment and secondary prevention, provided the problem of liver enzyme elevation and coronary events is resolved.

KEYWORDS

Venous thromboembolism treatment and secondary prevention - oral anticoagulation - low-molecular-weight heparin - synthetic pentasaccharides - ximelagatran - THRIVE

REFERENCES

• 1 Hawkins D. Pharmacoeconomics of thrombosis management.  Pharmacotherapy. 2004;  24 95S-99S
• 2 Silverstein M D, Heit J A, Mohr D N, Petterson T M, O'Fallon W M, Melton III L J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.  Arch Intern Med. 1998;  158 585-593
• 3 Anderson Jr F A, Wheeler H B, Goldberg R J et al.. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.  Arch Intern Med. 1991;  151 933-938
• 4 Turpie A G, Chin B S, Lip G Y. ABC of antithrombotic therapy: venous thromboembolism: treatment strategies.  BMJ. 2002;  325 948-950
• 5 Büller H R, Agnelli G, Hull R D, Hyers T M, Prins M H, Raskob G E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 401S-428S
• 6 Clagett G P, Reisch J S. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis.  Ann Surg. 1988;  208 227-240
• 7 Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society.  Lancet. 1992;  340 873-876
• 8 Schulman S, Rhedin A S, Lindmarker P et al.. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.  N Engl J Med. 1995;  332 1661-1665
• 9 Levine M N, Hirsh J, Gent M et al.. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.  Thromb Haemost. 1995;  74 606-611
• 10 Schulman S, Granqvist S, Holmstrom M et al.. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.  N Engl J Med. 1997;  336 393-398
• 11 Bounameaux H, de Moerloose P, Sarasin F P. Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs.  Blood Coagul Fibrinolysis. 1996;  7 507-514
• 12 Kearon C, Gent M, Hirsh J et al.. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.  N Engl J Med. 1999;  340 901-907
• 13 Fihn S D, Callahan C M, Martin D C, McDonell M B, Henikoff J G, White R H. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics.  Ann Intern Med. 1996;  124 970-979
• 14 Beyth R J, Quinn L M, Landefeld C S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.  Am J Med. 1998;  105 91-99
• 15 McMahan D A, Smith D M, Carey M A, Zhou X H. Risk of major hemorrhage for outpatients treated with warfarin.  J Gen Intern Med. 1998;  13 311-316
• 16 Ageno W, Huisman M V. Low-molecular-weight heparins in the treatment of venous thromboembolism.  Curr Control Trials Cardiovasc Med. 2000;  1 102-105
• 17 Warkentin T E. Heparin-induced thrombocytopenia.  Curr Hematol Rep. 2002;  1 63-72
• 18 Hirsh J, Levine M N. Low molecular weight heparin.  Blood. 1992;  79 1-17
• 19 Prandoni P, Lensing A W, Buller H R et al.. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.  Lancet. 1992;  339 441-445
• 20 Leizorovicz A, Simonneau G, Decousus H, Boissel J P. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis.  BMJ. 1994;  309 299-304
• 21 Lensing A W, Prins M H, Davidson B L, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis.  Arch Intern Med. 1995;  155 601-607
• 22 Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg J S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.  Am J Med. 1996;  100 269-277
• 23 Hirsh J, Fuster V, Ansell J, Halperin J L. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.  J Am Coll Cardiol. 2003;  41 1633-1652
• 24 Anderson Jr F A, Wheeler H B, Goldberg R J, Hosmer D W, Forcier A, Patwardhan N A. Physician practices in the prevention of venous thromboembolism.  Ann Intern Med. 1991;  115 591-595
• 25 Wong J E. Are patients with cancer receiving adequate treatment for thrombosis? Results from FRONTLINE.  Cancer Treat Rev. 2003;  29(Suppl 2) 11-13
• 26 Kakkar A K, Davidson B L, Haas S K. Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines.  J Thromb Haemost. 2004;  2 221-227
• 27 Lee A Y, Levine M N, Baker R I et al.. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  N Engl J Med. 2003;  349 146-153
• 28 Ridker P M, Goldhaber S Z, Danielson E et al.. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.  N Engl J Med. 2003;  348 1425-1434
• 29 Kearon C, Ginsberg J S, Kovacs M J et al.. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.  N Engl J Med. 2003;  349 631-639
• 30 Büller H R, Davidson B L, Decousus H et al.. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.  N Engl J Med. 2003;  349 1695-1702
• 31 Büller H R, Davidson B L, Decousus H et al.. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.  Ann Intern Med. 2004;  140 867-873
• 32 PERSIST Investigators . A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation.  J Thromb Haemost. 2004;  2 47-53
• 33 Schulman S, Wåhlander K, Lundström T, Clason S B, Eriksson H. THRIVE III Investigators. . Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.  N Engl J Med. 2003;  349 1713-1721
• 34 Fiessinger J N, Huisman M V, Davidson B L et al.. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.  JAMA. 2005;  293 681-689
• 35 Rickles F R, Levine M, Edwards R L. Hemostatic alterations in cancer patients.  Cancer Metastasis Rev. 1992;  11 237-248
• 36 Prandoni P, Lensing A W, Piccioli A et al.. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.  Blood. 2002;  100 3484-3488
• 37 Hutten B A, Prins M H, Gent M, Ginsberg J, Tijssen J G, Buller H R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.  J Clin Oncol. 2000;  18 3078-3083
• 38 Huisman M V, van der Meer F J, van Rooden C J, Prins M H. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism.  N Engl J Med. 2003;  349 2164-2167
• 39 Giangrande P L. Fondaparinux (Arixtra): a new anticoagulant.  Int J Clin Pract. 2002;  56 615-617
• 40 Weitz J I. New anticoagulants for treatment of venous thromboembolism.  Circulation. 2004;  110 I19-I26
• 41 Nijkeuter M, Huisman M V. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.  Curr Opin Pulm Med. 2004;  10 338-344
• 42 Samama M M, Gerotziafas G T. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).  Thromb Res. 2003;  109 1-11
• 43 Gustafsson D, Bylund R, Antonsson T et al.. A new oral anticoagulant: the 50-year challenge.  Nat Rev Drug Discov. 2004;  3 649-659
• 44 Lee W M, Larrey D, Olsson R et al.. Hepatic findings in long-term clinical trials of ximelagatran.  Drug Saf. 2005;  28 351-370
• 45 Wallentin L, Wilcox R G, Weaver W D et al.. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.  Lancet. 2003;  362 789-797
• 46 Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research .Cardiovascular and renal drugs advisory committee meeting. New Drug Application (NDA) 21-686, proposed trade name Exanta (ximelagatran) by AstraZeneca. Available at: http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4069T1.htm Accessed August 1, 2005